Comparison
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 vs 3m Syndrome 3 C3280146
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 2 Deficiency and 3M Syndrome 3 for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
A rare metabolic disorder affecting leucine breakdown. Infants may show developmental delay, seizures, and metabolic crises. Treatment involves biotin supplements and dietary protein restriction.
3m Syndrome 3 C3280146
A genetic condition causing intrauterine growth restriction and postnatal short stature with distinctive facial features. Treatment focuses on growth monitoring and supportive measures.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
0-null
3m Syndrome 3 C3280146
0-0
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
severe
3m Syndrome 3 C3280146
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
Chronic
3m Syndrome 3 C3280146
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
No
3m Syndrome 3 C3280146
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
metabolic
3m Syndrome 3 C3280146
musculoskeletal
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
metabolic
3m Syndrome 3 C3280146
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-2-deficiency-C1859499 and 3m-syndrome-3-C3280146 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 | 3m Syndrome 3 C3280146 | Discriminating power |
|---|---|---|---|
| Acute illness | May involve poor feeding, lethargy, seizures, or metabolic crisis, especially in infancy. | No metabolic crisis is described in the supplied source. | High |
| Growth pattern | Growth restriction is not described as the defining feature. | Intrauterine growth restriction and postnatal short stature are characteristic. | High |
| Facial or skeletal appearance | No distinctive skeletal phenotype is established by the supplied data. | Distinctive facial features may accompany the growth disorder. | Moderate |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 when
Leucine-pathway metabolites are abnormal
This raises suspicion for MCC deficiency but does not alone establish the diagnosis.
High
Illness-triggered neurologic or feeding deterioration
This pattern fits the described metabolic course better than a primary growth syndrome.
Moderate
MCCC2 findings are clinically correlated
Disease-specific genetic evidence can distinguish MCC2 deficiency from 3M syndrome.
High
Choose 3m Syndrome 3 C3280146 when
Prenatal and postnatal growth restriction
Persistent short stature after intrauterine growth restriction matches the described phenotype.
High
Distinctive facies with a growth disorder
This supports a genetic musculoskeletal condition rather than leucine-metabolism disease.
Moderate
3M syndrome type 3 genetic confirmation
Molecular results, commonly involving CCDC8, require specialist interpretation.
High
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 | 3m Syndrome 3 C3280146 | Interpretation |
|---|---|---|---|
| Organic acids and acylcarnitines | Leucine-pathway metabolites may be elevated; no cutoff is supplied. | Not a diagnostic test for 3M syndrome. | An abnormal result suggests, but does not prove, MCC deficiency. |
| Disease-specific genetic testing | MCCC2 variants may support the diagnosis when correlated clinically. | Testing for 3M syndrome type 3, commonly CCDC8, may support it. | Genetics distinguishes the disorders; variant interpretation belongs to specialists. |
| Growth and clinical assessment | No specific growth or skeletal pattern is established here. | Serial growth measurements and dysmorphology assessment are central. | Growth findings support evaluation but do not replace confirmation. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
- Outcome
- Variable and not predictable from these data; metabolic or developmental complications may occur.
- Factors
- Diagnostic certainty, intercurrent illness, feeding status, and specialist follow-up.
3m Syndrome 3 C3280146
- Outcome
- Usually a chronic growth disorder without described metabolic crises.
- Factors
- Degree of growth restriction, associated findings, and available supportive care.
Time frame: Both are chronic; metabolic risk may be most concerning in infancy and during illness.
Mortality and exact outcomes are not established here and require clinician interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Metabolic decompensation | Possible during illness or poor intake; occurrence varies. Not described in the supplied source. Urgent metabolic care applies only when MCC deficiency is suspected or confirmed. |
| Neurologic complications | Developmental delay or seizures may occur, but frequency is not established. Not established as core complications from the supplied description. Each developmental concern needs individualized clinician assessment. |
| Short stature | Not identified as the defining complication. Persistent short stature may affect function and psychosocial well-being. Management is supportive and should be individualized. |
Patient education highlights
- HighUrgent symptoms
For suspected MCC deficiency, seek urgent care for poor feeding, vomiting, lethargy, or seizures. This does not automatically apply to 3M syndrome.
- HighTest versus diagnosis
An abnormal screening or metabolite result is not a final diagnosis and needs clinician-directed confirmation.
- MediumCare approach
MCC care may include specialist-directed diet and biotin; 3M care emphasizes growth monitoring and support. Do not start restrictions independently.